Literature DB >> 8507808

Angiotensin II as a renal growth factor.

G Wolf, E G Neilson.   

Abstract

Angiotensin II (ANG II) can have multiple effects on the kidney, including influences on the regulation of glomerular hemodynamics and tubular transport as well as consequences for the glomerular processing of macromolecules. The recognized suppressive effects of angiotensin-converting enzyme inhibitors on compensatory renal growth, even in the absence of hemodynamic effects, and the well-documented proliferative effect of ANG II on vascular smooth muscle cells have provided the background for the recent intensive interest in this peptide as a renal cytokine. Diverse cell types along the nephron express a variety of ANG II receptors. These receptors and their putative signal transduction pathways have been best characterized in mesangial and proximal tubular cells. Culture experiments provide convincing evidence that ANG II can be a phenotypic influence on these cell types. The growth responses and the associated signal transduction pathways, however, are different in mesangial and proximal tubular cells. These ANG II-mediated responses are also associated with an increase in the synthesis of distinct collagen subtypes, potentially linking the growth stimulatory effects of ANG II to the irreversible changes of glomerulosclerosis and tubulointerstitial fibrosis observed in chronic renal failure. Preventing the intrarenal actions of ANG II with angiotensin-converting enzyme inhibitors or with the new, orally active, selective ANG II receptor antagonists may provide a rational therapeutic approach to attenuate the progression of a variety of kidney diseases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8507808     DOI: 10.1681/ASN.V391531

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  42 in total

1.  Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor.

Authors:  G Wolf; F N Ziyadeh; F Thaiss; J Tomaszewski; R J Caron; U Wenzel; G Zahner; U Helmchen; R A Stahl
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 2.  Trends in advanced glycation end products research in diabetes mellitus and its complications.

Authors:  José D Méndez; Jianling Xie; Montserrat Aguilar-Hernández; Verna Méndez-Valenzuela
Journal:  Mol Cell Biochem       Date:  2010-03-23       Impact factor: 3.396

Review 3.  Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.

Authors:  Ralph A DeFronzo; W Brian Reeves; Alaa S Awad
Journal:  Nat Rev Nephrol       Date:  2021-02-05       Impact factor: 28.314

Review 4.  Peritoneal damage by peritoneal dialysis solutions.

Authors:  Takafumi Ito; Noriaki Yorioka
Journal:  Clin Exp Nephrol       Date:  2008-02-15       Impact factor: 2.801

Review 5.  The role of tyrosine phosphorylation in angiotensin II mediated intracellular signaling and cell growth.

Authors:  B Schieffer; K E Bernstein; M B Marrero
Journal:  J Mol Med (Berl)       Date:  1996-02       Impact factor: 4.599

Review 6.  ACE inhibitors and proteinuria.

Authors:  R T Gansevoort; D de Zeeuw; P E de Jong
Journal:  Pharm World Sci       Date:  1996-12

Review 7.  Angiotensin II and the glomerulus: focus on diabetic kidney disease.

Authors:  James W Scholey
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

8.  Renin-angiotensin gene polymorphism in children with uremia and essential hypertension.

Authors:  Ferenc Papp; Aaron L Friedman; Csaba Bereczki; Ibolya Haszon; Eva Kiss; Emöke Endreffy; Sándor Túri
Journal:  Pediatr Nephrol       Date:  2002-12-18       Impact factor: 3.714

Review 9.  Regulating factors of renal tubular hypertrophy.

Authors:  G Wolf
Journal:  Clin Investig       Date:  1993-10

10.  Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells.

Authors:  S Kagami; W A Border; D E Miller; N A Noble
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.